Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

<p>Supplementary Table S2: Sample Summary. List of patients and samples (timepoints) included in the current study.</p>

Saved in:

书目详细资料
主要作者:	Stephanie Lheureux (16797697) (author)
其他作者:	Stephenie D. Prokopec (16797700) (author), Leslie E. Oldfield (16797703) (author), Eduardo Gonzalez-Ochoa (16375918) (author), Jeffrey P. Bruce (16797706) (author), Derek Wong (15135437) (author), Arnavaz Danesh (15135449) (author), Dax Torti (15135467) (author), Jonathan Torchia (16797709) (author), Alexander Fortuna (16797712) (author), Sharanjit Singh (16797715) (author), Matthew Irving (16797718) (author), Kayla Marsh (15135470) (author), Bernard Lam (15051558) (author), Vanessa Speers (16797721) (author), Aleksandra Yosifova (16797724) (author), Ana Oaknin (14956029) (author), Ainhoa Madariaga (15129719) (author), Neesha C. Dhani (16797727) (author), Valerie Bowering (16797730) (author), Amit M. Oza (15129737) (author), Trevor J. Pugh (14940894) (author)
出版:	2025
主题:	Cancer Methods and Technology Computational Methods Sequence analysis Gynecological Cancers Ovarian cancer Liquid Biopsy
标签:	添加标签没有标签, 成为第一个标记此记录!

_version_	1849927632785768448
author	Stephanie Lheureux (16797697)
author2	Stephenie D. Prokopec (16797700) Leslie E. Oldfield (16797703) Eduardo Gonzalez-Ochoa (16375918) Jeffrey P. Bruce (16797706) Derek Wong (15135437) Arnavaz Danesh (15135449) Dax Torti (15135467) Jonathan Torchia (16797709) Alexander Fortuna (16797712) Sharanjit Singh (16797715) Matthew Irving (16797718) Kayla Marsh (15135470) Bernard Lam (15051558) Vanessa Speers (16797721) Aleksandra Yosifova (16797724) Ana Oaknin (14956029) Ainhoa Madariaga (15129719) Neesha C. Dhani (16797727) Valerie Bowering (16797730) Amit M. Oza (15129737) Trevor J. Pugh (14940894)
author2_role	author author author author author author author author author author author author author author author author author author author author author
author_facet	Stephanie Lheureux (16797697) Stephenie D. Prokopec (16797700) Leslie E. Oldfield (16797703) Eduardo Gonzalez-Ochoa (16375918) Jeffrey P. Bruce (16797706) Derek Wong (15135437) Arnavaz Danesh (15135449) Dax Torti (15135467) Jonathan Torchia (16797709) Alexander Fortuna (16797712) Sharanjit Singh (16797715) Matthew Irving (16797718) Kayla Marsh (15135470) Bernard Lam (15051558) Vanessa Speers (16797721) Aleksandra Yosifova (16797724) Ana Oaknin (14956029) Ainhoa Madariaga (15129719) Neesha C. Dhani (16797727) Valerie Bowering (16797730) Amit M. Oza (15129737) Trevor J. Pugh (14940894)
author_role	author
dc.creator.none.fl_str_mv	Stephanie Lheureux (16797697) Stephenie D. Prokopec (16797700) Leslie E. Oldfield (16797703) Eduardo Gonzalez-Ochoa (16375918) Jeffrey P. Bruce (16797706) Derek Wong (15135437) Arnavaz Danesh (15135449) Dax Torti (15135467) Jonathan Torchia (16797709) Alexander Fortuna (16797712) Sharanjit Singh (16797715) Matthew Irving (16797718) Kayla Marsh (15135470) Bernard Lam (15051558) Vanessa Speers (16797721) Aleksandra Yosifova (16797724) Ana Oaknin (14956029) Ainhoa Madariaga (15129719) Neesha C. Dhani (16797727) Valerie Bowering (16797730) Amit M. Oza (15129737) Trevor J. Pugh (14940894)
dc.date.none.fl_str_mv	2025-11-25T13:21:49Z
dc.identifier.none.fl_str_mv	10.1158/1078-0432.30708436
dc.relation.none.fl_str_mv	https://figshare.com/articles/dataset/Supplementary_Table_S2_from_Identifying_Mechanisms_of_Resistance_by_Circulating_Tumor_DNA_in_EVOLVE_a_Phase_II_Trial_of_Cediranib_Plus_Olaparib_for_Ovarian_Cancer_at_Time_of_PARP_Inhibitor_Progression/30708436
dc.rights.none.fl_str_mv	CC BY info:eu-repo/semantics/openAccess
dc.subject.none.fl_str_mv	Cancer Methods and Technology Computational Methods Sequence analysis Gynecological Cancers Ovarian cancer Liquid Biopsy
dc.title.none.fl_str_mv	Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
dc.type.none.fl_str_mv	Dataset info:eu-repo/semantics/publishedVersion dataset
description	<p>Supplementary Table S2: Sample Summary. List of patients and samples (timepoints) included in the current study.</p>
eu_rights_str_mv	openAccess
id	Manara_cd5f611148684058c9c467c16bb504c7
identifier_str_mv	10.1158/1078-0432.30708436
network_acronym_str	Manara
network_name_str	ManaraRepo
oai_identifier_str	oai:figshare.com:article/30708436
publishDate	2025
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
rights_invalid_str_mv	CC BY
spelling	Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor ProgressionStephanie Lheureux (16797697)Stephenie D. Prokopec (16797700)Leslie E. Oldfield (16797703)Eduardo Gonzalez-Ochoa (16375918)Jeffrey P. Bruce (16797706)Derek Wong (15135437)Arnavaz Danesh (15135449)Dax Torti (15135467)Jonathan Torchia (16797709)Alexander Fortuna (16797712)Sharanjit Singh (16797715)Matthew Irving (16797718)Kayla Marsh (15135470)Bernard Lam (15051558)Vanessa Speers (16797721)Aleksandra Yosifova (16797724)Ana Oaknin (14956029)Ainhoa Madariaga (15129719)Neesha C. Dhani (16797727)Valerie Bowering (16797730)Amit M. Oza (15129737)Trevor J. Pugh (14940894)CancerMethods and TechnologyComputational MethodsSequence analysisGynecological CancersOvarian cancerLiquid Biopsy<p>Supplementary Table S2: Sample Summary. List of patients and samples (timepoints) included in the current study.</p>2025-11-25T13:21:49ZDatasetinfo:eu-repo/semantics/publishedVersiondataset10.1158/1078-0432.30708436https://figshare.com/articles/dataset/Supplementary_Table_S2_from_Identifying_Mechanisms_of_Resistance_by_Circulating_Tumor_DNA_in_EVOLVE_a_Phase_II_Trial_of_Cediranib_Plus_Olaparib_for_Ovarian_Cancer_at_Time_of_PARP_Inhibitor_Progression/30708436CC BYinfo:eu-repo/semantics/openAccessoai:figshare.com:article/307084362025-11-25T13:21:49Z
spellingShingle	Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression Stephanie Lheureux (16797697) Cancer Methods and Technology Computational Methods Sequence analysis Gynecological Cancers Ovarian cancer Liquid Biopsy
status_str	publishedVersion
title	Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
title_full	Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
title_fullStr	Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
title_full_unstemmed	Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
title_short	Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
title_sort	Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression
topic	Cancer Methods and Technology Computational Methods Sequence analysis Gynecological Cancers Ovarian cancer Liquid Biopsy

Supplementary Table S2 from Identifying Mechanisms of Resistance by Circulating Tumor DNA in EVOLVE, a Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer at Time of PARP Inhibitor Progression

相似书籍